文献速递肿瘤 PET/CT

临床前PERCIST与25%SUVmax阈值:三阴性乳腺癌PDX模型中18F-FDG PET疗效评估的精准影像

Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-clinical 18F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts.
PubMed 文献 · J Nucl Med · 2019-11-22

本研究在三阴性乳腺癌患者来源异种移植瘤(PDX)共临床试验中,优化18F-FDG PET定量指标以评估多西他赛联合卡铂治疗反应。结果显示25%SUVmax阈值(SUV25)重复性高(变异性<9%),临床前PERCIST在α=0.7、β=2.8时一致性和重复性最佳,且与SUV25肿瘤摄取高度相关。定量反应评估评分支持将SUV25和14 mm3球体的SUVpeak(SUVP14)作为评估治疗反应的最佳指标。

要点

  • SUV25阈值(25%SUVmax)重复性高,变异性<9%。
  • 临床前PERCIST在α=0.7、β=2.8时一致性和重复性最佳。
  • 定量反应评估评分支持SUV25和SUVP14作为评估治疗反应的最佳影像指标。

核心结论

  • 定量反应评估评分支持将SUV25(25%SUVmax阈值)和14 mm3球体的SUVpeak(SUVP14)作为评估治疗反应的最佳影像指标。

研究设计与样本

  • 在三阴性乳腺癌PDX共临床试验中,采用重测方案优化18F-FDG PET SUV阈值、SUVpeak指标和临床前PERCIST参数的重复性。
  • 于基线及治疗后4天进行18F-FDG PET显像,评估影像指标评估治疗反应的重复性、准确性、变异性和性能。

主要发现

  • 25%SUVmax阈值(SUV25)具有高度重复性(变异性<9%)。
  • 临床前PERCIST在α=0.7和β=2.8时一致性和重复性最大化,并与SUV25肿瘤摄取测量高度相关,后者与代谢肿瘤的SUV相关。

关键数值与推荐

  • SUV25定义为25%SUVmax阈值,重复性变异性<9%。
  • 临床前PERCIST参数取α=0.7和β=2.8时一致性和重复性最佳。
  • SUVP14定义为14 mm3球体的SUVpeak。

临床怎么用

  • 在临床前18F-FDG PET评估三阴性乳腺癌PDX治疗反应时,可优先考虑SUV25和SUVP14作为定量影像指标。
  • 采用临床前PERCIST时,建议参考α=0.7和β=2.8的参数设置以获得最佳一致性和重复性。

局限性

  • 需进一步研究以全面表征SUV25和临床前PERCIST SUVP14在广泛治疗方案和PDX模型中的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Numerous recent works highlight the limited utility of established tumor cell lines in recapitulating the heterogeneity of tumors in patients. More realistic preclinical cancer models are thought to be provided by transplantable, patient-derived xenografts (PDXs). The inter- and intratumor heterogeneity of PDXs, however, presents several challenges in developing optimal quantitative pipelines to assess response to therapy. The objective of this work was to develop and optimize image metrics for 18F-FDG PET to assess response to combination docetaxel and carboplatin therapy in a co-clinical trial involving triple-negative breast cancer PDXs. We characterized the reproducibility of standardized uptake value (SUV) metrics to assess response to therapy, and we optimized a preclinical PERCIST paradigm to complement clinical standards. Considerations in this effort included variability in tumor growth rate and tumor size, solid tumors versus tumor heterogeneity and a necrotic phenotype, and optimal selection of tumor slices versus whole tumor. Methods: A test-retest protocol was implemented to optimize the reproducibility of 18F-FDG PET SUV thresholds, SUVpeak metrics, and preclinical PERCIST parameters. In assessing response to therapy, 18F-FDG PET imaging was performed at baseline and 4 d after therapy. The reproducibility, accuracy, variability, and performance of imaging metrics to assess response to therapy were determined. We defined an index called the Quantitative Response Assessment Score to integrate parameters of prediction and precision and thus aid in selecting the optimal image metric to assess response to therapy. Results: Our data suggest that a threshold of 25% of SUVmax (SUV25) was highly reproducible (<9% variability). The concordance and reproducibility of preclinical PERCIST were maximized at α = 0.7 and β = 2.8 and exhibited a high correlation with SUV25 measures of tumor uptake, which in turn correlated with the SUV of metabolic tumor. Conclusion: The Quantitative Response Assessment Score favors SUV25 followed by SUVpeak for a sphere with a volume of 14 mm3 (SUVP14) as optimal metrics of response to therapy. Additional studies are warranted to fully characterize the utility of SUV25 and preclinical PERCIST SUVP14 as image metrics for response to therapy across a wide range of therapeutic regimens and PDX models.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Savaikar MA, Whitehead T, Roy S, et al. Preclinical PERCIST and 25% of SUVmax Threshold: Precision Imaging of Response to Therapy in Co-clinical 18F-FDG PET Imaging of Triple-Negative Breast Cancer Patient-Derived Tumor Xenografts. J Nucl Med. 2019. PMID: 31757841. doi:10.2967/jnumed.119.234286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。